A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology by Klaus Bühler et al.
Bühler et al. Reproductive Biology and Endocrinology 2014, 12:6
http://www.rbej.com/content/12/1/6RESEARCH Open AccessA large, multicentre, observational, post-marketing
surveillance study of the 2:1 formulation of
follitropin alfa and lutropin alfa in routine clinical
practice for assisted reproductive technology
Klaus Bühler1*, Olaf GJ Naether2 and Wilma Bilger3Abstract
Background: Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) both have a role to play in follicular
development during the natural menstrual cycle. LH supplementation during controlled ovarian stimulation (COS)
for assisted reproductive technology (ART) is used for patients with hypogonadotropic hypogonadism. However,
the use of exogenous LH in COS in normogonadotropic women undergoing ART is the subject of debate. The aim
of this study was to investigate characteristics of infertile women who received the 2:1 formulation of follitropin alfa
and lutropin alfa (indicated for stimulation of follicular development in women with severe LH and FSH deficiency)
in German clinical practice.
Methods: A 3-year, multicentre, open-label, observational/non-interventional, post-marketing surveillance study of
women (21-45 years) undergoing ART. Primary endpoint: reason for prescribing the 2:1 formulation of follitropin alfa
and lutropin alfa. Secondary variables included: COS duration/dose; oocytes retrieved; fertilization; clinical pregnancy;
ovarian hyperstimulation syndrome (OHSS).
Results: In total, 2220 cycles were assessed; at least one reason for prescribing the 2:1 formulation was given in
1834/2220 (82.6%) cycles. Most common reasons were: poor ovarian response (POR) (39.4%), low baseline LH
(17.8%), and age (13.8%). COS: mean dose of the 2:1 formulation on first day, 183.1/91.5 IU; mean duration,
10.8 days. In 2173/2220 (97.9%) cycles, human chorionic gonadotrophin was administered. Oocyte pick-up (OPU)
was attempted in 2108/2220 (95.0%) cycles; mean (standard deviation) 8.0 (5.4) oocytes retrieved/OPU cycle.
Fertilization (≥1 oocyte fertilized) rates: in vitro fertilization (IVF), 391/439 (89.1%) cycles; intracytoplasmic sperm
injection (ICSI)/IVF + ICSI, 1524/1613 (94.5%) cycles. Clinical pregnancy rate: all cycles, 25.9%; embryo transfer
cycles, 31.3%. OHSS: hospitalization for OHSS, 8 (0.36%) cycles, Grade 2, 60 (2.7%), and Grade 3, 1 (0.05%).
Conclusions: In German routine clinical practice, the most common reasons for using the 2:1 formulation of
follitropin alfa and lutropin alfa for women undergoing ART were POR, low baseline LH, and age. Severe OHSS
incidence was low and similar to that reported previously.
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Follicle-stimulating hormone (FSH) and luteinizing
hormone (LH) are involved in the natural menstrual
cycle and both have a role to play in follicular devel-
opment [1]. FSH stimulates follicular development,
both LH and FSH are required for oestradiol (E2) syn-
thesis, and LH appears to be required for steroido-
genesis to occur [1]. In fact, an increase in serum
FSH typical of the luteal–follicular transition is a key
part of stimulation of ovarian follicle recruitment [2].
In the remaining part of the follicular phase, lower
FSH levels mean that no further emergence of imma-
ture follicles occurs; at this point, the growth and
maturation of the dominant follicle is supported by
increases in LH levels [2].
Women with abnormally low levels of LH and FSH
caused by severely reduced hypothalamic or pituitary ac-
tivity are classified as having World Health Organization
Group I anovulatory infertility or hypogonadotropic hypo-
gonadism (HH) [3,4]. It is generally considered that LH
supplementation during controlled ovarian stimulation
(COS) for assisted reproductive technology (ART) should
be used in patients with HH [1,4,5]. However, there has
been considerable debate over the use of exogenous LH in
COS in normogonadotropic women undergoing ART
[1,2,6]. The use of long gonadotrophin-releasing hormone
agonist protocols causes profound pituitary suppression,
which results in reduced LH levels that are similar to
those that characterize HH (for which exogenous LH
supplementation is recommended) [1]. Currently, stud-
ies investigating the use of exogenous LH for COS in
normogonadotropic women have yielded conflicting
results [1]. However, there is evidence to suggest that
specific patient subgroups of normogonadotropic women
may benefit from LH supplementation during COS: for
example, in women aged ≥35 years and in women with a
poor ovarian response [5,7-9]. Also, the use of exogenous
LH may be beneficial in women with a hyporesponse to
FSH (defined as a normal response in the number of
recruited follicles, but requiring an increased and/or
prolonged FSH stimulation to continue and complete
follicular growth) [10].
Currently, FSH alone is commercially available as
urine-derived or recombinant formulations, whereas
LH alone is only available as a recombinant formula-
tion. In addition, a 2:1 formulation of recombinant hu-
man (r-h)FSH and r-hLH (in a fixed-dose combination
of 150 IU r-hFSH [follitropin alfa]:75 IU r-hLH [lutropin
alfa]) has been developed [11-13]. This 2:1 formulation of
follitropin alfa and lutropin alfa is indicated for the stimu-
lation of follicular development in women with severe LH
and FSH deficiency (defined by an endogenous serum LH
level of <1.2 IU/L) [14] and has been available in Germany
since October 2007.To investigate the characteristics of women who re-
ceived the 2:1 formulation of follitropin alfa and lutropin
alfa in routine clinical practice in Germany, a 3-year
post-marketing surveillance study was initiated. The study
explored the reasons why physicians chose to treat women
with the 2:1 formulation of follitropin alfa and lutropin
alfa, as well as how they defined the characteristics of pa-
tients who may benefit from supplemental LH in daily
practice. An interim analysis of data from 919 ART cycles
collected between January and November 2008 has been
reported previously [3]. In the current report, we present
ART treatment cycle data for the full 3 years.
Methods
ART procedures were conducted according to standard
practice in Germany at the time of the study – embryo
selection was not permitted, no more than three em-
bryos could be transferred, and supernumerary two-
pronuclear (2PN) oocytes could be cryopreserved for
future use [15].
Study design
This was a 3-year, multicentre, open-label, observational
(non-interventional), post-marketing surveillance study
(Clinicaltrials.gov identifier: NCT01112618; Merck Serono
protocol number RH002) that collected data from 45
fertility treatment centres in Germany.
The objective of this study was to investigate the char-
acteristics of women who received treatment with the
2:1 formulation of follitropin alfa and lutropin alfa.
Data were collected from women aged 21–45 years
undergoing ART cycles. All patients received the 2:1 for-
mulation of r-hFSH and r-hLH (in a fixed-dose combin-
ation of 150 IU r-hFSH [follitropin alfa]:75 IU r-hLH
[lutropin alfa], Merck Serono S.A., Geneva, Switzerland,
a subsidiary of Merck KGaA, Darmstadt, Germany).
Combination treatment with follitropin alfa for dose
adaptation was permitted (in accordance with prescrib-
ing information) [14]. Cycles involving combination
treatment of the 2:1 formulation with clomiphene cit-
rate, human menopausal gonadotrophin, urine-derived
FSH, follitropin beta, or lutropin alfa were excluded
from the analysis. In addition, cycles were excluded that
used frozen 2PN oocytes created during previous cycles.
Only one cycle per patient was to be included in the
analysis; if information was available on >1 cycle per pa-
tient, data from the earliest cycle were analysed.
Data collection
All data were recorded anonymously.
Prior to initiation of treatment, the treating physician
completed a questionnaire which included a question on
the patient’s clinical presentation that led to a diagnosis
of severe LH deficiency and, thus, prescribing the 2:1
Table 1 Baseline demographic and clinical characteristics
Characteristic
(mean [SD])
Age subgroup All patients


























































AFC = antral follicle count; AMH = anti-Müllerian hormone; BMI = body mass
index; E2 = oestradiol; FSH = follicle-stimulating hormone; LH = luteinizing
hormone; SD = standard deviation.
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more of the following reasons could be selected: low
baseline LH level; low baseline E2 level; thin endome-
trium; amenorrhoea; and/or ‘other’. Endometrial thickness
prior to COS, baseline E2 and LH (on cycle days 2–4)
levels, and the presence of amenorrhoea were recorded.
Age, body mass index (BMI), antral follicle count (AFC),
baseline FSH (cycle days 2–4), and anti-Müllerian hor-
mone (AMH) levels could also be recorded (optional). The
questionnaires were sent for data analysis by ANFOMED
(ANFOMED GmbH, Möhrendorf, Germany).
In addition, the physician prospectively entered rou-
tine clinical and laboratory data for the treatment cycles
into a standardized electronic data collection system
‘RecDate’ [16]. The RecDate software system enables the
collection, documentation, and evaluation of reproduc-
tive medicine data. Clinical pregnancy was recorded; this
was defined as transvaginal ultrasound identification of
an (intra- or extra-uterine) gestational sac, but also in-
cluded extrauterine pregnancies or miscarriages con-
firmed by histological evidence. Follow-up data on
pregnancy outcomes were collected for 18 months after
the initial study period.
Outcome measures
The primary outcome measure was the reason for diag-
nosis of severe LH deficiency and, thus, for prescribing
the 2:1 formulation of follitropin alfa and lutropin alfa.
Secondary outcome measures relating to the 2:1 formu-
lation of follitropin alfa and lutropin alfa received were:
the dose on the first and last days of treatment; whether
a consistent dose was used throughout COS; the dura-
tion of COS; and the total dose received. Treatment
outcome measures included the number of oocytes re-
trieved, rate of fertilization, and clinical pregnancy rate;
available follow-up data were also reported.
Reporting of adverse events and adverse drug reactions
is not required in German post-marketing surveillance
studies. However, the overall incidence of ovarian hyper-
stimulation syndrome (OHSS; any Grade) and the inci-
dence of OHSS Grades 2 and 3 were reported. Grade 1
OHSS was considered a normal response to COS.
Statistical analysis
No calculations of sample size or statistical power were
undertaken. No statistical hypotheses were pre-specified.
Descriptive statistics were provided (means, standard de-
viations [SD], frequencies, and percentages). In addition,
data for subgroups of patients according to age (≤35 and
>35 years) were reported.
Results
The study was conducted between January 2008 and
December 2010. A total of 3825 questionnaires werereceived from 45 centres in Germany. Following matching
with the RecDate database, 2220 ART cycles using the 2:1
formulation of follitropin alfa and lutropin alfa in women
aged 21–45 years were identified; these cycles were from
42 centres.
Patient characteristics
For the 2220 cycles assessed, baseline demographic and
clinical characteristics for the overall patient population
and according to age group (≤35 years and >35 years)
are shown in Table 1. The mean (SD) age of patients
was 36.5 (4.00) years, the mean (SD) BMI was 23.1
(3.98), and the mean endometrial thickness was 3.41
(2.45) mm. For the 180 cycles with AMH data reported,
the mean (SD) AMH level was 1.7 (2.06) ng/mL; the me-
dian AMH level was 1.0 ng/mL (lower and upper quar-
tiles: 0.4 and 2.1 ng/mL). There were 1528/2220 (68.8%)
patients aged >35 years. FSH and E2 levels at baseline
and endometrial thickness were similar in both age
groups. However, baseline LH and AMH levels and AFC
were higher in patients aged ≤35 years than in the older
subgroup of patients.
Primary outcome measure
At least one reason for prescribing the 2:1 formulation
of follitropin alfa and lutropin alfa was given for 1834/
2220 (82.6%) cycles (Figure 1). Physicians gave one
pre-specified reason in 1780 cycles and more than one
pre-specified reason in 54 cycles (Figure 1a). The pre-
specified answer of ‘other’ was analysed further by ‘ac-
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Figure 1 The reasons cited by physicians for prescribing the 2:1 formulation of follitropin alfa and lutropin alfa for 1834/2220 assisted
reproductive technology (ART) cycles. (a) The number of reported pre-specified reasons (one or more reasons could be given; 1889 reasons
were given for 1834 ART cycles); (b) Expansion of the pre-specified answer of ‘other’ (1315 responses of other were given in total; the six reasons
cited most frequently are shown). Percentages are based on 1889 reasons. GnRH = gonadotrophin-releasing hormone; LH = luteinizing hormone.
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most frequently (including the expansion of the cat-
egory ‘other’) were: poor ovarian response (744/1889;
39.4%); low baseline LH level (336/1889; 17.8%); age




Data on the duration of COS were missing for three cy-
cles. The mean (SD) duration of COS using the 2:1 for-
mulation of follitropin alfa and lutropin alfa was 10.8
(2.90) days (2217 cycles; Table 2). In most (2107/2217;
95.0%) cycles, COS lasted for 6–15 days.
Similar mean doses of the 2:1 formulation of follitro-
pin alfa and lutropin alfa were used on the first and last
day of COS: 183.1/91.5 IU and 181.8/90.9 IU, respec-
tively. The data according to age subgroup showed thatlower mean doses of the 2:1 formulation of follitropin
alfa and lutropin alfa were used (on the first and last
days of COS and in total) in patients aged ≤35 years
than in older patients (Table 2).
In most (2076/2220; 93.5%) cycles, the 2:1 formulation
of follitropin alfa and lutropin alfa was the only treatment
used for COS. Dose adaptation using follitropin alfa was
reported in 144/2220 (6.5%) cycles. The mean (SD) dose
of additional follitropin alfa was 1982.7 (1038.4) IU. Data
on dose were available for 2074 cycles, in which only the
2:1 formulation of follitropin alfa and lutropin alfa was
used for COS. In these cycles, most (1875/2074; 90.4%)
used a consistent dose throughout COS: one vial (150/
75 IU) in 908/2074 cycles; two vials (300/150 IU) in 538/
2074 cycles; three vials (450/225 IU) in 324/2074 cycles;
and other doses in 105/2074 cycles. The dose of the 2:1
formulation of follitropin alfa and lutropin alfa was ad-
justed during treatment in 199/2074 cycles. The dose was




Age subgroup All patients (n = 2220)b
≤35 years (n = 692) >35 years (n = 1528)
Duration of COS, days 11.0 (3.36) (n = 690) 10.7 (2.67) (n = 1527) 10.8 (2.90) (n = 2217)
Dosec on first day
of COS, IU
163.1/81.6 [= 244.7]
(65.37/32.68 [= 98.05]) (n = 567)
192.0/96.02 [= 288.1]
(80.71/40.36 [= 121.07]) (n =1258)
183.1/91.5 [= 274.6]
(77. 4/38.7 [= 116.1]) (n = 1825)
Dosec on last day
of COS, IU
168.11/84.06 [= 252.17]
(71.12/35.56 [= 106.68]) (n = 531)
187.89/93.95 [= 281.84]
(85.99/42.99 [= 128.98]) (n = 1199)
181.8/90.9 [= 272.7]
(82. 2/41.1 [= 123.3]) (n = 1730)
Total dosec required, IU 1617.2/808.6 [= 2425.8]
(995.3/497.6 [= 1492.9]) (n = 648)
2064.2/1032.1 [= 3096.3]
(1115.4/557.7 [= 1673.1]) (n = 1409)
1923.4/961.7 [= 2885.1]
(1098.6/549.3 [= 1647.9]) (n = 2057)
aThe number of cycles for which each COS variable was reported varied.
bThe total number of cycles reported in this study was 2220; however, the duration of COS was unavailable for three cycles.
cDose of the 2:1 formulation of follitropin alfa and lutropin alfa.
SD = standard deviation.
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porarily changed in 24 patients.Treatment outcomes
In 2173/2220 (97.9%) cycles, human chorionic gonado-
trophin was administered to trigger ovulation, and in
2108/2220 (95.0%) cycles, oocyte pick-up (OPU) was
attempted (Table 3). A mean (SD) number of 8.0 (5.40)
oocytes were retrieved per OPU cycle (Table 3). A slightly
higher mean number of oocytes were retrieved per OPU
cycle in patients aged ≤35 years (n = 670) than in patients
aged >35 years (n = 1438): 9.3 (5.85) versus 7.4 (5.07)Table 3 Oocyte pick-up (OPU), embryo transfer (ET), and
pregnancy rates for assisted reproductive technology
cycles
Outcome Age subgroup All
patients≤35 years >35 years


















































The study evaluated data for 2220 assisted reproductive technology cycles; the
percentages given in the table were calculated from different denominators
as indicated.
aOPU cycles.
bET was not performed in 388 cycles.
cET cycles.
dImplantation rate is defined as the number of (intra- and extra-uterine)
gestational sacs/number of transferred embryos.
hCH = human chorionic gonadotrophin; SD = standard deviation.oocytes, respectively, although the difference was not ana-
lysed statistically.
The embryo transfer (ET) rate, number of embryos
transferred, and implantation rate are presented in
Table 3.
In vitro fertilization (IVF) alone was used in 439 cy-
cles, intracytoplasmic sperm injection (ICSI; or a com-
bination of IVF and ICSI) was used in 1613 cycles.
Fertilization of at least one oocyte was achieved in 391/
439 (89.1%) IVF cycles and in 1524/1613 (94.5%) ICSI
(or a combination of IVF and ICSI) cycles.Clinical pregnancy and follow-up
Clinical pregnancy was achieved in 574 cycles (25.9% of
all cycles or 31.3% of ET cycles). The clinical pregnancy
rate per ET cycle was 41.3% in patients aged ≤35 years
and 26.3% in those aged >35 years.
Eighteen-month follow-up data were available for 458
patients. A total of 318 pregnancies resulted in live
births: 258 singleton live births; 56 twins; and 4 resulted
in higher multiple births.
There were 140 miscarriages; the miscarriage rate per
reported clinical pregnancy was 24.4% (140/574), or
using the follow-up dataset, the miscarriage rate was
30.6% (140/458). The baseline characteristics for patients
who had a clinical pregnancy and experienced a miscar-
riage are shown in Table 4.
There were fewer miscarriages in patients aged ≤35 years
(51/255, 20.0% per reported clinical pregnancy; 51/198,
25.8% follow-up dataset) than in patients aged >35 years
(89/319, 27.9% per reported clinical pregnancy; 89/260,
34.2% follow-up dataset).Ovarian hyperstimulation syndrome
OHSS (of any grade) was reported in 337/2220 (15.2%) cy-
cles, hospitalization due to OHSS in 8 (0.36%) cycles, and
Grade 1, Grade 2 and Grade 3 OHSS were reported in
268 (12.1%), 60 (2.7%), and 1 (0.05%) cycles, respectively.
Table 4 Key baseline characteristics for the ‘miscarriage’
and ‘no miscarriage’ subgroups who had a clinical
pregnancy
Baseline characteristic Miscarriage No miscarriage
Age, years 36.0 (4.35) (n = 140) 34.9 (3.88) (n = 434)
FSH level, IU/L 9.5 (11.50) (n = 34) 10.1 (12.41) (n = 114)
LH level, IU/L 3.9 (5.09) (n = 83) 4.2 (7.79) (n = 268)
AMH level, ng/mL 2.8 (3.90) (n = 10) 1.9 (1.48) (n = 32)
In total, there were 574 women in the ‘miscarriage’ and ‘no miscarriage’
subgroups who had a clinical pregnancy.
All values are mean (standard deviation).
AMH = anti-Müllerian hormone; FSH = follicle-stimulating hormone;
LH = luteinizing hormone.
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This large (2220 ART cycles), 3-year post-marketing sur-
veillance study provides valuable information on routine
clinical practice in Germany regarding the use of the 2:1
formulation of follitropin alfa and lutropin alfa. It is im-
portant to investigate how clinicians are using fertility
treatments in clinical practice as their prescribing habits
may be influenced by evidence in the published litera-
ture. The reason cited most frequently for prescribing
the 2:1 formulation of follitropin alfa and lutropin alfa in
ART cycles was ‘poor ovarian response’ (39% of reported
reasons), with low baseline LH level (18%) being the sec-
ond most frequently cited reason. Age (14%) and low en-
dogenous E2 level (7%) were the next most commonly
cited reasons.
Information on the dose of the 2:1 formulation of folli-
tropin alfa and lutropin alfa used for COS in ART cycles
revealed that in the overall population, the mean first
and last doses administered were similar (183.1/91.5 and
181.8/90.9 IU, respectively). In addition, the mean (SD)
duration of COS was 10.8 (2.90) days. Furthermore, as
expected, higher doses of the 2:1 formulation were used
in women aged >35 years than in the younger age group.
The rate of started cycles where ET was not performed
in this study (388/2220; 17.5%) was similar to that re-
ported in the 2010 German IVF Registry (64,348/75,928
plausible cycles; ~15%) [17].
The use of the 2:1 formulation of follitropin alfa and lu-
tropin alfa for COS during routine clinical practice was ef-
fective in achieving pregnancies in ART cycles, with a
clinical pregnancy rate per ET cycle of 31.3%. In the two
age groups studied, clinical pregnancy rate per ET cycle
was markedly different, with the rate being lower in older
women as might be expected. The German IVF Registry re-
ports annual data on women undergoing ART [15,17,18].
The clinical pregnancy rates reported here for women aged
≤35 years (41.3%) and >35 years (26.3%) are similar to those
from prospectively collected cycles reported in the German
IVF Registry (2008–2010): clinical pregnancy rates (per ET
cycle) of 34.2–39.5% for women aged ≤34 years and 13.7–
28.9% for women aged ≥35 years.Approximately 70% of the current study population
was aged ≥35 years. This might be expected as there is a
general trend for delayed childbearing in Western soci-
eties [19], with many couples seeking ART for this rea-
son [20]. However, although a recent study has failed
to find differences in outcomes for women ≥35 years
treated with or without LH supplementation during
COS [21], there are a growing number of studies that
have demonstrated a benefit from LH supplementation
[5], which may have contributed to older patients be-
ing prescribed the 2:1 formulation of follitropin alfa
and lutropin alfa and consequently entering this study.
For example, in a recent meta-analysis of data from pa-
tients aged ≥35 years (7 randomized controlled trials;
902 ART cycles) r-hLH supplementation of r-hFSH for
COS resulted in higher implantation (odds ratio [OR]:
1.36; 95% confidence interval [CI]: 1.05, 1.78) and clin-
ical pregnancy (OR: 1.37; 95% CI: 1.03, 1.83) rates than
r-hFSH alone [22].
The rate of miscarriage reported in this study (24.4%)
was slightly higher than those reported in the German
IVF Registry in 2009 and 2010 (18.4–18.7% for fresh ET
and 23.3% for frozen ET [calculated per clinical preg-
nancy; all ages combined]) [15,17]. However, it should
be kept in mind that a large proportion of patients in
the current study were aged ≥35 years, and advanced
maternal age has been linked to a greater risk of foetal
loss [19,23].
Our study indicates that the 2:1 formulation of follitro-
pin alfa and lutropin alfa has a favourable profile in
terms of OHSS (1 case of Grade 3 OHSS [0.05% cycles]
and 8 cases of OHSS requiring hospitalization [0.36% cy-
cles]). This finding is supported by previous data on the
2:1 formulation of follitropin alfa and lutropin alfa [14].
Furthermore, the rate of Grade 3 OHSS reported here is
lower than that reported in the German IVF Registry in
2009 (0.27%) and 2010 (0.23%) per stimulation protocol
(n = 41,925 and n = 41,102, respectively) [15,17]. How-
ever, the low incidence of OHSS reported in the present
study may be expected from the population of patients
studied as they were likely to have a low ovarian
response.
The key strength of this observational study is the use of
the RecDate database, which provided prospective docu-
mentation of treatment cycles at approximately 85% of all
German fertility centres during 2008 to 2010 [6]. Thus, our
findings may be considered to reflect normal clinical ART
practice in Germany and, therefore, offer valuable insights
into the use of the 2:1 formulation of follitropin alfa and lu-
tropin alfa. Furthermore, the large number of observations
included in this investigation were collected without the
strict inclusion or exclusion criteria that are mandatory in
a randomized controlled trial or meta-analysis and so are
likely to reflect routine clinical practice more accurately.
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post-marketing surveillance study and the intrinsic limi-
tations of such a study design. This type of study relies
on the reporting of data under less stringent conditions
than those in a randomized clinical trial. As such, some
data sets in the current study are incomplete (and the
number of patients with evaluable data was different for
each outcome). Furthermore, there is the potential for
variability in responses submitted by physicians to the
questionnaire, as responses depended on the clinical
opinion of each physician. For example, individual physi-
cians may have used a different definition of ‘poor ovar-
ian response’, such as patients who had a poor response
to previous cycles or those with an expected poor re-
sponse for other reasons. A standardized definition of a
poor response to COS was published in 2011 [24] after
the current study had been completed.
In summary, the three reasons cited most frequently
for the use of the 2:1 formulation of follitropin alfa and
lutropin alfa were poor ovarian response, low baseline
LH level, and age. The pregnancy rates reported here
using the 2:1 formulation of follitropin alfa and lutropin
alfa were similar to those reported in the German IVF
Registry during the same time frame; the incidence of
severe OHSS reported in this study was low and similar
to that reported previously.
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